Lifecore Biomedical, Inc. (NASDAQ:LFCR) Receives Average Rating of “Hold” from Analysts

Lifecore Biomedical, Inc. (NASDAQ:LFCR) has received a consensus recommendation of “Hold” from the five brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $5.50.

LFCR has been the subject of a number of research analyst reports. Barrington Research raised Lifecore Biomedical from a “market perform” rating to an “outperform” rating and set a $5.50 price target for the company in a research note on Tuesday, March 17th. Zacks Research raised Lifecore Biomedical to a “hold” rating in a research report on Thursday, January 1st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Lifecore Biomedical in a research note on Thursday, January 22nd.

Lifecore Biomedical Stock Performance

Lifecore Biomedical stock opened at $4.02 on Tuesday. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. The firm has a market capitalization of $150.67 million, a P/E ratio of -4.10 and a beta of 0.62. Lifecore Biomedical has a 1-year low of $3.90 and a 1-year high of $8.98. The company’s 50-day moving average is $7.25 and its 200 day moving average is $7.39.

Lifecore Biomedical (NASDAQ:LFCR) last announced its earnings results on Monday, March 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The business had revenue of $35.75 million for the quarter, compared to analysts’ expectations of $35.31 million. Lifecore Biomedical had a negative net margin of 23.08% and a negative return on equity of 1,211.09%. Research analysts forecast that Lifecore Biomedical will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC lifted its holdings in Lifecore Biomedical by 86.2% during the 4th quarter. Millennium Management LLC now owns 251,705 shares of the company’s stock valued at $2,059,000 after buying an additional 116,500 shares in the last quarter. AQR Capital Management LLC grew its stake in Lifecore Biomedical by 28.4% in the 4th quarter. AQR Capital Management LLC now owns 16,171 shares of the company’s stock worth $132,000 after acquiring an additional 3,574 shares in the last quarter. Jump Financial LLC bought a new position in Lifecore Biomedical in the 4th quarter worth about $123,000. Price T Rowe Associates Inc. MD increased its position in shares of Lifecore Biomedical by 20.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company’s stock worth $137,000 after acquiring an additional 2,826 shares during the period. Finally, State of Wisconsin Investment Board increased its position in shares of Lifecore Biomedical by 138.2% during the fourth quarter. State of Wisconsin Investment Board now owns 37,825 shares of the company’s stock worth $309,000 after acquiring an additional 21,946 shares during the period. Hedge funds and other institutional investors own 83.36% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.